Ramoplanin topical

Drug Profile

Ramoplanin topical

Alternative Names: A-16686; A-16686A; MDL-62198

Latest Information Update: 12 Aug 2008

Price : $50

At a glance

  • Originator Pfizer
  • Class Antiacnes; Antibacterials; Depsipeptides
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Staphylococcal infections

Most Recent Events

  • 12 Aug 2008 No development reported - Phase-II for Staphylococcal infections in USA (Topical)
  • 11 Sep 2005 Vicuron Pharmaceuticals has been acquired and merged into Pfizer
  • 31 Mar 2003 Versicor is now called Vicuron Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top